$127.22
0.32% today
NYSE, Aug 22, 04:46 pm CET
ISIN
US66987V1098
Symbol
NVS

Novartis ADR Stock price

$126.82
+12.68 11.11% 1M
+17.47 15.98% 6M
+29.51 30.33% YTD
+9.21 7.83% 1Y
+46.93 58.74% 3Y
+45.03 55.05% 5Y
+34.46 37.31% 10Y
+80.43 173.40% 20Y
NYSE, Closing price Thu, Aug 21 2025
-0.43 0.34%
ISIN
US66987V1098
Symbol
NVS
Industry

Key metrics

Basic
Market capitalization
$241.0b
Enterprise Value
$266.6b
Net debt
$25.6b
Cash
$6.7b
Shares outstanding
1.9b
Valuation (TTM | estimate)
P/E
18.2 | 14.6
P/S
4.4 | 4.3
EV/Sales
4.9 | 4.7
EV/FCF
15.9
P/B
5.7
Dividends
DPS
$3.99
Yield 1Y | 5Y
3.2% | 3.7%
Growth 1Y | 5Y
6.8% | 6.4%
Payout 1Y | 3Y
63.7% | 63.3%
Increased
6 Years
Financials (TTM | estimate)
Revenue
$54.8b | $56.4b
EBITDA
$18.6b | $22.7b
EBIT
$18.3b | $20.4b
Net Income
$13.7b | $16.8b
Free Cash Flow
$16.8b
Growth (TTM | estimate)
Revenue
12.2% | 9.0%
EBITDA
45.4% | 37.1%
EBIT
44.8% | 25.3%
Net Income
-15.6% | 40.9%
Free Cash Flow
41.3%
Margin (TTM | estimate)
Gross
76.1%
EBITDA
33.9% | 40.2%
EBIT
33.5%
Net
24.9% | 29.9%
Free Cash Flow
30.6%
Financial Health
Equity Ratio
43.1%
Return on Equity
27.1%
ROCE
25.2%
ROIC
21.6%
Debt/Equity
0.8
More
EPS
$7.0
FCF per Share
$8.7
Short interest
0.2%
Employees
76k
Rev per Employee
$680.0k
Show more

Is Novartis ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,015 stocks worldwide.

Novartis ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

31 Analysts have issued a Novartis ADR forecast:

13x Buy
42%
14x Hold
45%
4x Sell
13%

Analyst Opinions

31 Analysts have issued a Novartis ADR forecast:

Buy
42%
Hold
45%
Sell
13%

Financial data from Novartis ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
54,842 54,842
12% 12%
100%
- Direct Costs 13,098 13,098
6% 6%
24%
41,744 41,744
14% 14%
76%
- Selling and Administrative Expenses 13,132 13,132
5% 5%
24%
- Research and Development Expense 9,678 9,678
9% 9%
18%
18,608 18,608
45% 45%
34%
- Depreciation and Amortization 262 262
115% 115%
0%
EBIT (Operating Income) EBIT 18,346 18,346
45% 45%
33%
Net Profit 13,654 13,654
16% 16%
25%

In millions USD.

Don't miss a Thing! We will send you all news about Novartis ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Novartis ADR Stock News

Neutral
GlobeNewsWire
4 days ago
PRESS RELEASE Two VictORION studies will highlight Leqvio's impact on patient quality of life, and as a cholesterol lowering monotherapy Lp(a)FRONTIERS APHERESIS study will assess effect of pelacarsen on reducing need for lipoprotein apheresis – a cholesterol removal procedure similar to dialysis PARACHUTE-HF study will highlight the efficacy and safety of Entresto to treat heart failure with r...
Negative
The Motley Fool
5 days ago
Pharmaceutical companies regularly encounter substantial headwinds. Among the most significant are patent cliffs -- when therapies lose patent exclusivity, inviting cheaper generic or biosimilar competition that erodes their market share.
Positive
The Motley Fool
7 days ago
We've seen several investing trends sweep through Wall Street in recent years, from excitement about the cannabis market to the artificial intelligence (AI) industry that's now dominating headlines. Some of these opportunities turned out to be major disappointments, while others were major moneymakers.
More Novartis ADR News

Company Profile

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Head office Switzerland
CEO Vasant Narasimhan
Employees 75,883
Founded 1996
Website www.novartis.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today